Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories reports that it has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, authorizing commercialization, sale and distribution in Canada. The approval covers 2 mg/pen and 4 mg/pen strengths at 1.34 mg/mL and does not have a fixed expiry date. Dr. Reddy’s states it is the first company to obtain market authorization for generic Semaglutide Injection in Canada and has launch preparations underway. The company highlights that GLP‑1 receptor agonist therapies such as Semaglutide are supported by extensive clinical evidence for improving glycemic control in adults with type 2 diabetes and notes that Canada is recognized as the world’s second‑largest market for Semaglutide.
Dr. Reddy’s Laboratories filed a Form 6-K to notify investors that it will release its Q4 and full-year FY26 results for the period ended March 31, 2026 on Tuesday, May 12, 2026, after a Board meeting.
The company will distribute the financial results through stock exchanges, media, its website, and email, and will host an earnings call on May 12, 2026 at 19:30 IST / 10:00 ET. An audio recording and transcript of the call, as well as a press meet presentation, will be made available on its website.
Dr. Reddy’s Laboratories filed a Form 6-K explaining the status of its Semaglutide Injection in Canada after a media report. The company confirms the news headline is accurate: it is still awaiting Health Canada’s approval, referred to as a Notice of Compliance, for this product.
Dr. Reddy’s notes that, as part of the ongoing regulatory review, it received Drug Identification Numbers (DINs) for Semaglutide Injection from Health Canada on April 22, 2026. The company states it remains engaged with the regulator and intends to bring the product to the Canadian market once approval is granted. It also clarifies that, at this stage, there is no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.
Dr. Reddy’s Laboratories Limited submitted a Form 6-K stating that its Board of Directors will consider, among other items, a proposal for recommending a final dividend for FY 2025-26, if any. The company notes this update is in continuation of an earlier intimation dated March 23, 2026.
Dr. Reddy’s Laboratories Limited reports that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories LLC in Russia, has received a final penalty decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia. The decision relates to Value Added Tax on marketing services reclassified as taxable services.
The Russian tax authority set the penalty at RUB 9.27 million (approximately INR 11.40 million), reduced from an originally quantified amount of RUB 20.09 million (approximately INR 24.50 million). The company states that this penalty has no material impact on its financials, operations or other activities.
DR REDDYS LABORATORIES LTD executive Munnirpallam Madhu Sundar Subramanian, Global Head of Quality and PV, filed an initial ownership report showing his current stake in the company. The Form 3 lists direct ownership of 35,600 Equity Shares, without indicating any recent purchase or sale activity.
Dr. Reddy’s Laboratories Limited has entered into an agreement to sell its entire shareholding in its wholly owned subsidiary Svaas Wellness Limited to Enspirit Technology Services Private Limited. The agreement and completion of the sale both occurred on April 7, 2026.
Svaas Wellness Limited reported turnover of Rs. 28.5 Crore in FY 2025, all from Dr. Reddy’s Laboratories Limited, representing about 0.09% of consolidated turnover. The sale consideration is INR 2.23 Cr, and Svaas Wellness Limited will cease to be a wholly owned subsidiary. The buyer is not part of the promoter group and the deal is not a related party transaction.
DR REDDYS LABORATORIES LTD executive Patrick Rudolf Aghanian, Head - Europe Generics, filed an initial insider ownership report. The filing shows direct beneficial ownership of 8,450 Equity Shares underlying ADRs, with no reported purchases or sales associated with this filing.
DR REDDYS LABORATORIES LTD executive Milan Kantilal Kalawadia, CEO – North America, has filed an initial Form 3 reporting his ownership in the company. The filing lists 47,325 Equity Shares underlying ADRs held with direct ownership, and does not report any recent purchases or sales.
DR REDDYS LABORATORIES LTD executive Motupalli Venkata Ramana, who serves as CEO - Global Generics, has filed an initial ownership report showing direct holdings of 68,230 Equity Shares of the company. This Form 3 reflects his beneficial ownership position rather than a new buy or sell transaction.